High-Dosage of Epirubicin and Cyclophosphamide may cause AML

Adjuvant chemotherapy with epirubicin and cyclophosphamide for early breast cancer// patients increased the risk of Acute myeloid leukemia or Myelodysplastic syndrome. Recent study published in Journal of clinical oncology reports that early breast cancer patients undergoing chemotherapy with ...

Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer

... Cardiac toxicity may also occur at lower cumulative doses (400 mg/m2) in patients with prior mediastinal irradiation or who are receiving concurrent cyclophosphamide therapy Acute infusion-related reactions including, but not limited to, flushing, shortness of breath, facial swelling, headache, ...

Gene Can Dampen Chemo Drug Effectiveness

...sphamide, an agent used against breast tumors, blood cancers and other malignancies. The research is the first to show a mechanism and a biomarker for cyclophosphamide resistance. Although this is not good news for some patients, the findings have a silver lining: New tests may soon be developed to help doctors sc...

GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer

...arlier Stages The companies also announced today the initiation of an additional Phase III study of ofatumumab in combination with fludarabine and cyclophosphamide (FC) for patients with CLL when initial treatment no longer works (second-line treatment). The open-label study will randomize 352 patients to evaluat...

Hypertension & cholesterol medications present in water released into the St. Lawrence River

...reducing medication), enalapril (hypertension medication), methotrexate and cyclophosphamide (two products used in the treatment of certain cancers) have all been detec...because of the large quantities prescribed by physicians. "Methotrexate and cyclophosphamide are two products very often used to treat cancer and are more likely to be ...

US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium

...rial of adjuvant docetaxel/cyclophosphamde plus trastuzumab in HER2+ early stage breast cancer patients." -- Dr. Jones' study, "Docetexal plus cyclophosphamide is cost-effective compared to doxorubicin plus cyclophosphamide, based on an economic analysis of US Oncology Trial 9735: Additional rational to avoid...

New therapy prevents dangerous side effect for lymphoma patients

...at The University of Texas M. D. Anderson Cancer Center report today at the 50th annual meeting of the American Society of Hematology. Pentostatin, cyclophosphamide and rituximab together are providing the same remission rate as other combinations but with minimal long-term bone marrow suppression, said study pres...

Late-breaking data to be presented at the American Society of Hematology Annual Meeting

...regardless of previous treatment regimens." Rituximab, Fludarabine, and cyclophosphamide (R-FC) Prolongs Progression-Free Survival in Relapsed or Refractory Chronic...ix 28-day cycles of fludarabine (25 mg/m2 intravenously on days 1 to 3) and cyclophosphamide (250 mg/m2 intravenously on days 1 to 3) alone (FC) or in combination with ...

Novel treatments show improvements in survival and response rates for leukemia and lymphoma

...py With Fludarabine, Cyclophosphamide, and Rituximab Versus Fludarabine and cyclophosphamide Improves Response Rates and Progression-Free Survival of Previously Untreat...ix 28-day cycles of fludarabine (25 mg/m2 intravenously on days 1 to 3) and cyclophosphamide (FC) (250 mg/m2 intravenously on days 1 to 3) alone or FCR (375 mg/m2 int...

Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma

... Fludarabine, Cyclophosphamide, and Ritux i mab Versus Fludarabine and cyclophosphamide I m proves R e sponse Rates and Progression-Free Survival of Pr e ...x 28-day cycles of fludarabine (25 mg/m^2 intravenously on days 1 to 3) and cyclophosphamide (FC) (250 mg/m^2 intravenously on days 1 to 3) alone or FCR (375 mg/m^2 int...

Cyclophosphamide in Medical Technology

New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel

22 US Oncology Affiliated Physicians Participate in ASCO Proceedings HOUSTON, June 04, 2007 /PRNewswire/ -- A leading cancer researcher affiliated with the US Oncology Research Network presented findings from a randomized, multicenter phase III trial that compared the disease-free survival (DFS) o...

Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer

... also occur at lower cumulative doses (400 mg/m2) in patients with prior mediastinal irradiation or who are receiving concurrent cyclophosphamide therapy * Acute infusion-related reactions including, but not limited to, flushing, shortness of breath, facial swelling, headache, chills...

New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer

...bine (X) is 11:45 hrs Cancer Group integrated into docetaxel (T) General 5-FU + epirubicin + cyclophosphamide Session 7 (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim ana...

Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL

...th Del 17p In this analysis, researchers evaluated Campath in combination with the standard treatment regimen known as FCR (fludarabine, cyclophosphamide and rituximab) as front-line therapy to a high-risk group of CLL patients. Of the 60 patients intended for analysis in the CFAR group, 48 wer...

New Study Shows PCR and FCR Have Significant Activity in B-cell Chronic Lymphocytic Leukemia

...omising results have been reported with the combination of fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) by Keating and colleagues at the University o...Mayo Clinic and MSKCC trials, evaluated the combination of pentostatin (P), cyclophosphamide (C), and rituximab (R) (PCR); results suggested similar efficacy with less ...

Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients

...a median of four cycles (range: 2-11 cycles), which were presented by Shaji Kumar, M.D., Mayo Clinic, showed: -- The maximum tolerated dose of cyclophosphamide in the VcDCR regimen was not reached. The recommended doses for the Phase II portion of the trial include 500 mg/m(2) of cyclophosphamide, the highest...

Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting

...less of previous treatment regimens." Rituximab, Fludarabine, and cyclophosphamide (R-FC) Prolongs Progression-Free Survival in Relapsed or Refractor...x 28-day cycles of fludarabine (25 mg/m^2 intravenously on days 1 to 3) and cyclophosphamide (250 mg/m^2 intravenously on days 1 to 3) alone (FC) or in combination with...

The Leukemia & Lymphoma Society and Memgen Announce New Chronic Lymphocytic Leukemia Clinical Trial

... an immune-boosting molecule, ISF35 (Immune Stimulatory Factor 35), followed by three courses of rituximab plus the chemotherapy drugs fludarabine and cyclophosphamide (FCR). "This clinical study builds upon three previous trials already completed at M.D. Anderson and here at UCSD," said Januario E. Castro, ...

Genmab A/S - Company Announcement: Recruitment Completed In Ofatumumab CLL Front Line Study

...nts in the Phase II study of ofatumumab in combination with fludarabine and cyclophosphamide to treat front line CLL. Genmab A/S (OMX: GEN) announced today it has com...II study of ofatumumab (HuMax-CD20 (R)) in combination with fludarabine and cyclophosphamide (FC) to treat chronic lymphocytic leukemia (CLL) in previously untreated pa...

Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma

...eloma. The results showed the status of 28 evaluable patients, who received cyclophosphamide at 300 mg/m2 on days 1, 8, 15, 22, VELCADE at 1.3 mg/m2 on days 1, 4, 8 and...rough 18 for one cycle and on days 1 through 4 for cycles two through four. cyclophosphamide at 3 g/m2 and G-CSF were used to harvest stem cells. Patients were then con...

Cyclophosphamide in Biological News

Hypertension and cholesterol medications present in water released into the St. Lawrence River

...reducing medication), enalapril (hypertension medication), methotrexate and cyclophosphamide (two products used in the treatment of certain cancers) have all been detec...because of the large quantities prescribed by physicians. "Methotrexate and cyclophosphamide are two products very often used to treat cancer and are more likely to be ...

New chemotherapy combo produces side effects, but no extra efficacy, in early breast cancer patients

...has the effect of reducing patient compliance, so, given all these factors we would recommend staying with current standard treatments epirubicin and cyclophosphamide followed by a taxane, or TAC, another commonly used three-drug combination of docetaxel, doxorubicin and cyclophosphamide, said Professor von Minckwit...

Oncolytics Biotech, Inc. announces publication of research

...and safety of various combinations of reovirus and cyclophosphamide in vivo. The paper, entitled cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneou...ted the initiation of our combination REOLYSIN and cyclophosphamide clinical trial, recently approved by the U.K. heal...

CSHL scientists identify and repress breast cancer stem cells in mouse tissue

... cancer has the potential to actually enrich the subpopulation of stem-like cells that serve as cancer progenitors. We found that administration of cyclophosphamide in our mouse cell sample had the effect of enriching for these cells, Hannon said, which suggests that we need to look carefully at these therapies in...

Dealing deadly cancers a knockout punch

...in further detail in future preclinical work. Another presentation at the Arizona conference reported on the use of Reolysin plus the cancer drug cyclophosphamide in an animal model of melanoma. When treated with both agents, test animals experienced enhanced tumor regression compared with either agent alone, an...

Botox could help target resistant tumors for treatment

...mulation of apoptosis (programmed cellular death) when compared by irradiation without Botox. The combination of Botox and the chemotherapeutic agent cyclophosphamide showed significantly stunted tumor growth after three days, as well. Since Botox is used in clinics without serious toxicity, the study indicates ...

NCI Researchers Confirm the Effectiveness of Immunotherapy Approach to Treating Melanoma

...n the blood that can attack tumors, were separated from other parts of the blood. Next, patients were treated for two days with the chemotherapy agent cyclophosphamide followed by five days of fludarabine. The chemotherapy drugs were used to reduce the number of lymphocytes circulating in the blood, therefore reducin...

Effective Cancer Treatments Follow The Clock

... in mice, the scientists found that the body's internal biological clock affects the survival of immune cells that are targets of the anti-cancer drug cyclophosphamide (CY). “We became interested in examining this issue because there is a long history of knowledge that chemotherapeutic agents produce different mor...

Cyclophosphamide in Biological Technology

Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment

CALGARY, Jan. 7 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ('Oncolytics') reported today that a research group led by Dr. Richard Vile of the Mayo Clinic College of Medicine in Rochester, Minnesota, published the results of its work testing the antitumor efficacy...

Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide

CALGARY, Oct. 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for its Clinical Trial Application (CTA) to begin a clinica...

Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

... Cardiac toxicity may also occur at lower cumulative doses (400 mg/m2) in patients with prior mediastinal irradiation or who are receiving concurrent cyclophosphamide therapy Acute infusion-related reactions including, but not limited to, flushing, shortness of breath, facial swelling, head...

Health Robotics Announces Results of the European Union-Sponsored SafeChemo Project

...ation has also been tested using cyclophosphamide. We were unable to detect cyclophosphamide above a detection limit of one picogram*/ml after having handled multiple cyclophosphamide doses in concentrations of 1g/50ml." Dr. Alicia Tavella, Oncology Ph...

Oncolytics Biotech Inc. Announces 2008 Second Quarter Results

...er trial using systemic and intraperitoneal administration of REOLYSIN(R). - Started patient enrolment in a U.K. combination REOLYSIN(R) and cyclophosphamide trial. - Subsequent to the quarter end, announced that the 200th patient had been treated with REOLYSIN(R). Preclinical Advances - Two pres...

First Taxane-Based Non-Anthracycline Containing Chemotherapy in Combination With Herceptin (TCH) for HER2 Positive Early Breast Cancer Patients Obtains Approval From the FDA

...Survival (DFS) and Overall Survival (OS), compared to AC-T (doxorubicin and cyclophosphamide followed by docetaxel) and a 5-fold lower cardiotoxicity compared to AC-...-containing control regimen consisting of doxorubicin (A, 60 mg/m2) plus cyclophosphamide (C, 600 mg/m2) every three weeks for four cycles followed by Taxotere(R)...

Oncolytics Biotech Inc. Announces 2008 First Quarter Results

...g the antitumor efficacy and safety of various combinations of reovirus and cyclophosphamide in vivo. The paper, entitled "Cyclophosphamide Facilitates Antitumor Effica...ties. The data support investigation in human clinical trials of the use of cyclophosphamide prior to systemic reovirus administration to modulate, but not ablate, the ...

ProMetic presents preclinical data for prostate and pancreatic cancer at the AACR Meeting

...cancer both in vitro and in vivo. The in vivo study demonstrated a significant reduction in tumor volume both alone (p < 0.05) and in combination with cyclophosphamide (p < 0.01). Dr. Lyne Gagnon, ProMetic's Director of Research and Development, Biology, presented preclinical data on the PBI-0110 alone and in combi...

Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007

... Drug Administration (FDA) to conduct a Phase II melanoma trial with REOLYSIN(R); - Approval to begin a Phase I combination REOLYSIN(R) and cyclophosphamide trial in the U.K.; - In January 2008, the NCI filed a protocol with the U.S. FDA to conduct a Phase I/II ovarian, peritoneal and fallopian tube...

Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer

...l 9735 at 2007 San Antonio Breast Cancer Symposium Showed Taxotere(R) and cyclophosphamide Improved Overall Survival Versus An Anthracycline Combination SAN ANT...emotherapy combination of Taxotere(R) (docetaxel) Injection Concentrate and cyclophosphamide significantly improved overall survival compared to standard chemotherapy. ...